Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Diabetes Obes Metab ; 11 Suppl 1: 25-30, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19143812

ABSTRACT

AIM: The goal of this study was to develop and implement methodology that would aid in the analysis of extended high-density single nucleotide polymorphism (SNP) major histocompatibility complex (MHC) haplotypes combined with human leucocyte antigen (HLA) alleles in relation to type 1 diabetes risk. METHODS: High-density SNP genotype data (2918 SNPs) across the MHC from the Type 1 Diabetes Genetics Consortium (1240 families), in addition to HLA data, were processed into haplotypes using PedCheck and Merlin, and extended DR3 haplotypes were analysed. RESULTS: With this large dense set of SNPs, the conservation of DR3-B8-A1 (8.1) haplotypes spanned the MHC (>/=99% SNP identity). Forty-seven individuals homozygous for the 8.1 haplotype also shared the same homozygous genotype at four 'sentinel' SNPs (rs2157678 'T', rs3130380 'A', rs3094628 'C' and rs3130352 'T'). Conservation extended from HLA-DQB1 to the telomeric end of the SNP panels (3.4 Mb total). In addition, we found that the 8.1 haplotype is associated with lower risk than other DR3 haplotypes by both haplotypic and genotypic analyses [haplotype: p = 0.009, odds ratio (OR) = 0.65; genotype: p = 6.3 x 10(-5), OR = 0.27]. The 8.1 haplotype (from genotypic analyses) is associated with lower risk than the high-risk DR3-B18-A30 haplotype (p = 0.01, OR = 0.23), but the DR3-B18-A30 haplotype did not differ from other non-8.1 DR3 haplotypes relative to diabetes association. CONCLUSION: The 8.1 haplotype demonstrates extreme conservation (>3.4 Mb) and is associated with significantly lower risk for type 1 diabetes than other DR3 haplotypes.


Subject(s)
Diabetes Mellitus, Type 1/genetics , HLA-DR3 Antigen/genetics , Polymorphism, Single Nucleotide/genetics , Conserved Sequence , Genetic Predisposition to Disease/genetics , Genotype , Haplotypes , Heterozygote , Homozygote , Humans , Pedigree , Risk Factors
2.
Genes Immun ; 7(7): 550-4, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16929349

ABSTRACT

The major susceptibility locus for type 1 diabetes mellitus (T1D) maps to the human lymphocyte antigen (HLA) class II region in the major histocompatibility complex on chromosome 6p21. In southern European populations, like the Basques, the greatest risk to T1D is associated with DR3 homo- and heterozygosity and is comparable to that of DR3/DR4, the highest risk genotype in northern European populations. Celiac disease (CD) is another DR3-associated autoimmune disorder showing certain overlap with T1D that has been explained by the involvement of common genetic determinants, a situation more frequent in DR3-rich populations, like the Basques. As both T1D- and CD-associated HLA alleles are part of conserved extended haplotypes (CEH), we compared DR3-homozygous T1D and CD patients to determine whether CEHs were equally distributed between both disorders or there was a differential contribution of different haplotypes. We observed a very pronounced distribution bias (P<10(-5)) of the two major DR3 CEHs, with DR3-B18 predominating in T1D and DR3-B8 in CD. Additionally, high-density single nucleotide polymorphism (SNP) analysis of the complete CEH [A*30-B*18-MICA*4-F1C30-DRB1*0301-DQB1*0201-DPB1*0202] revealed extraordinary conservation throughout the 4.9 Mbp analyzed supporting the existence of additional diabetogenic variants (other than HLA-DRB1*0301-DQB1*0201), conserved within the DR3-B18 CEH (but not in other DR3 haplotypes) that could explain its enhanced diabetogenicity.


Subject(s)
Celiac Disease/genetics , Celiac Disease/immunology , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , HLA-DR3 Antigen/genetics , Female , Gene Frequency , Genetic Predisposition to Disease , Haplotypes , Homozygote , Humans , Male , Polymorphism, Single Nucleotide , Spain
3.
Hautarzt ; 46(2): 87-93, 1995 Feb.
Article in German | MEDLINE | ID: mdl-7706078

ABSTRACT

In 77 patients with port-wine stain under 18 years of age we performed 100 test treatments with the flashlamp-pumped pulsed dye laser (585 nm, 450 microseconds, 5 mm beam diameter). In 54% of cases we could obtain excellent or good lightening with one test treatment. In only 9% of cases did the patients show bad or no response to laser therapy. In the following treatment of larger areas (n = 125), the rate of good or excellent lightening was even higher (60%). Side effects were infrequent and consisted mostly of transient hyperpigmentation. In contrast to argon laser therapy, the flashlamp-pumped pulsed dye laser is safe and effective for treatment of port-wine stains in childhood and adolescence. Our results and the good results reported in the literature confirm the flashlamp-pumped pulsed dye laser as the laser of choice for port-wine stain treatment in young patients.


Subject(s)
Hamartoma/surgery , Laser Therapy/instrumentation , Skin Neoplasms/surgery , Adolescent , Child , Child, Preschool , Dermatologic Surgical Procedures , Facial Neoplasms/pathology , Facial Neoplasms/surgery , Female , Follow-Up Studies , Hamartoma/pathology , Humans , Infant , Male , Skin/pathology , Skin Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...